Penicillin Allergy De-labeling Results in Significant Changes in Outpatient Antibiotic Prescribing Patterns

Thomas Hills¹,², Nicola Arroll³, Eamon Duffy⁴, Janice Capstick¹, Anthony Jordan¹ and Penny Fitzharris¹

¹ Department of Immunology, Auckland District Health Board, Auckland, New Zealand, ² Medical Research Institute of New Zealand, Wellington, New Zealand, ³ Health Information and Technology Service, Auckland District Health Board, Auckland, New Zealand, ⁴ Department of Infectious Diseases, Auckland District Health Board, Auckland, New Zealand

Unverified penicillin allergies are common but most patients with a penicillin allergy label can safely use penicillin antibiotics. Penicillin allergy labels are associated with poor clinical outcomes and overuse of second-line antibiotics. There is increasing focus on penicillin allergy “de-labeling” as a tool to improve antibiotic prescribing and antimicrobial stewardship. The effect of outpatient penicillin allergy de-labeling on long-term antibiotic use is uncertain. We performed a retrospective pre- and post- study of antibiotic prescribing patterns, from an electronic dispensing data repository, in patients undergoing penicillin allergy assessment at Auckland City Hospital, New Zealand. Over a mean follow-up of 4.55 years, 215/304 (70.7%) of de-labeled patients were dispensed a penicillin antibiotic. Rates of penicillin antibiotic dispensing were 0.24 (0.18–0.30) penicillin courses per year before de-labeling and 0.80 (0.67–0.93) following de-labeling with a reduction in total antibiotic use from 2.30 (2.06–2.54) to 1.79 (1.59–1.99) antibiotic courses per year. In de-labeled patients, the proportion of antibiotic courses that were penicillin antibiotics increased from 12.81 to 39.62%. Rates of macrolide, cephalosporin, trimethoprim/co-trimoxazole, fluoroquinolone, “other” non-penicillin antibiotic use, and broad-spectrum antibiotic use were all lower following de-labeling. Further, antibiotic costs were lower following de-labeling. In this study, penicillin allergy de-labeling was associated with significant changes in antibiotic dispensing patterns.

Keywords: penicillin, antibiotic, allergy, hypersensitivity, prescribing, electronic dispensing data, antimicrobial stewardship

INTRODUCTION

Penicillin allergy labels (PALs) are common with 8–25% of individuals labeled as allergic to penicillin, depending on the patient group studied (1). PALs are intended to protect patients from receiving antibiotics that may cause direct harm due to allergic drug reactions. However, most patients with a PAL will tolerate penicillin antibiotics because these labels are frequently inaccurate. Inaccurate PALs occur because of the overdiagnosis of antibiotic allergy in the context of...
non-allergic childhood rashes, misclassification of non-allergic adverse reactions, and because true IgE-mediated allergy can wane with time (2–4). A PAL itself is not benign and the presence of a PAL is associated with poor outcomes including increased length of hospital stay (5), increased risk of infection with multi-resistant organisms (5–7), increased rates of Clostridium difficile diarrhea (7), inappropriate antibiotic prescribing and overuse of second-line antibiotics (8), more surgical site infections (9), increased costs (10), and increased mortality (6).

Clarifying a patient’s penicillin allergy status has the potential to improve their access to appropriate and safe antibiotic therapy while also contributing to antimicrobial stewardship efforts in the era of increasing antimicrobial resistance (11, 12). Assessment in a specialist antibiotic allergy clinic with access to penicillin allergy skin testing and observed oral penicillin challenges (drug provocation tests) is a widely-used approach; there is extensive evidence that this is safe and that the majority of patients assessed will tolerate penicillin antibiotics (that is, they are not allergic and can be de-labeled) (3, 12–15). Antibiotic allergy assessment and de-labeling meant 59/62 (95.2%) patients were willing to use the de-labeled antibiotic (16). However, prescribers must also be willing to prescribe the relevant antibiotic and, in some settings, the persistence of PALs despite negative observed oral penicillin challenges has been identified as a significant issue (17–19). Hospital inpatients, de-labeled during an admission when penicillin antibiotics are indicated, will typically use the penicillin antibiotic immediately (12, 20). There is a relative paucity of data on patterns of longer-term antibiotic use in de-labeled patients, particularly in the outpatient setting.

Electronic dispensing data repositories are powerful potential tools for research on community antibiotic use (21). The pattern of antibiotic use before and after assessment in our clinic is unknown. The great majority of antibiotic use occurs in the community. In New Zealand, at 95% of total antibiotic consumption, the proportion of total antibiotic consumption that occurs in the community is higher than in other countries (22). Therefore, community antibiotic consumption is a key metric in studies seeking to measure changes in antibiotic use, particularly in New Zealand.

Electronic pharmacy dispensing records allow the direct comparison of community antibiotic dispensing before and after penicillin allergy evaluation. Here, we contrast antibiotic prescribing before and after penicillin allergy de-labeling through the analysis of several years of pharmacy dispensing records, thus providing information on antibiotic use over longer periods than previously reported. We characterize the use of specific non-penicillin antibiotics that are important targets for antimicrobial stewardship efforts. Further, we compare both the antimicrobial spectrum and cost of antibiotics dispensed before and after de-labeling.

**Abbreviations:** PAL, penicillin allergy label; PEFR, peak expiratory flow rate; FEV1, forced expiratory volume in 1 s; SaO2, oxygen saturations by pulse oximetry; SPT, skin prick testing; IDT, intradermal testing.

**MATERIALS AND METHODS**

**Inclusion and Exclusion Criteria**

Adult patients who underwent an observed penicillin challenge through the Penicillin Allergy Clinic in the Department of Clinical Immunology at Auckland City Hospital between 01/01/2012 and 31/12/2017 were identified from electronic records of Immunology Day Ward attendances. There are approximately 70 penicillin challenges performed through the Antibiotic Allergy Clinic at Auckland City Hospital annually. Further, those with positive penicillin skin testing were identified from electronic records of penicillin skin testing results in the Penicillin Allergy Clinic in the same time period. Patients were excluded from the final analysis if they were aged < 15 years at the time of assessment, if they had no medication entries in the TestSafe database prior to assessment, and if they had no antibiotic dispensing entries in the TestSafe database across the pre- and post-assessment periods.

**Skin Testing and Penicillin Challenge Methodology**

Penicillin skin tests were performed by medical laboratory scientists using increasing doses of commercial testing reagents (Diater Laboratories, Madrid, Spain). Skin prick testing (SPT) was followed by intradermal testing (IDT) using a standard protocol with a total of either three or five testing steps, as outlined in the Supplementary Methods. Positive skin testing results were adjudicated by the immunology clinician on the day of the testing based on a wheal size 3 mm greater than a saline control for SPT and an increase of wheal size of 3 mm over the saline control (0.02 ml) for IDT. Antibiotic challenges were performed under observation on the Immunology Day Ward with informed consent and monitoring of vital signs. Challenges were either performed as graded challenges, with the majority of these single-blinded, or as an un-blinded single observed dose. The outcome of the penicillin challenge was adjudicated by an immunology clinician on the day of the challenge. A challenge was determined to be positive when any of the following occurred: conjunctival reaction, respiratory tract symptoms or PEFR/FEV1 decrease ≥ 15%, cutaneous reactions (pruritus, erythema, urticaria, or angioedema), hypotension, laryngeal oedema, SaO2 fall, or anaphylaxis. A challenge was deemed to be negative if a patient received a dose of 500 mg of amoxicillin, 625 mg (500 + 125 mg) of amoxicillin with clavulanic acid (Augmentin), 500 mg of flucloxacillin, or 500 mg of phenoxyethylpenicillin, and when none of the aforementioned clinical observations occurred.

**Dispensing Data Extract**

Electronic community pharmacy antibiotic dispensing records for patients in the study cohort were retrieved from the “TestSafe” pharmacy dispensing record repository; this repository contains community pharmacy dispensing records for patients living in four of the ten District Health Boards in the catchment area for our clinic. Patients can opt to have their dispensing records excluded from the TestSafe database. For these reasons, coverage is not universal in our clinic population. Dispensing
records specifically relating to oral and intravenous antibiotics were identified by ATC code (see Supplementary Table 1), grouped into antibiotic classes, and categorized as either occurring prior to or following each individual patient’s allergy assessment. Information on topical antibiotics and other systemic antimicrobials, such as antiviral or antifungal medications, was not collected. The pre-assessment time period was defined as the time between the first TestSafe dispensing entry (for any medication, including non-antibiotic medications) and the date of assessment in our clinic (either for an antibiotic challenge or, if skin testing was positive, the date of skin testing). The post-assessment time period was defined as the time between the date of assessment in our clinic and the date of the data extract (19/09/2019).

Outcomes
The primary outcome of the study was the change in penicillin antibiotic dispensing rates before and after penicillin allergy assessment, stratified by allergy assessment outcome (two groups: penicillin allergy de-labeled and penicillin allergy confirmed). Secondary outcomes, all stratified by allergy assessment outcome, were: the change in non-penicillin antibiotic dispensing rates (including for the non-penicillin antibiotics described in Supplementary Table 1), the change in penicillin antibiotic dispensing measured as a proportion of total antibiotic courses, the change in non-penicillin antibiotic dispensing (including for specific families of penicillin antibiotics outlined in Supplementary Table 1) measured as a proportion of total antibiotic courses, the change in average direct cost of antibiotic, and the change in the proportion of antibiotics that were classified as broad-spectrum.

Statistical Analyses and Ethical Approvals
Dispensing rates and proportions after assessment were compared with those before assessment using paired t-tests and Wilcoxon matched-pairs signed rank tests when data were non-parametric. This study was reviewed and approved by the Auckland Health Research Ethics Committee (AHREC 000130).

RESULTS
Patients with a positive (evidence of allergy) or negative (no evidence of allergy) penicillin challenge in the Auckland City Hospital Immunology Clinic between 01/01/2012 and 31/12/2017 were identified. There were 483 negative challenges and 17 positive challenges. A review of skin testing records from the same clinic identified 43 patients who were labeled as penicillin allergic based on positive skin test results without an oral challenge. Antibiotic dispensing data, defined as at least one dispensing record for an antibiotic in either the pre- or post-intervention period, was available for 304/483 (62.9%) negative challenge patients, 12/17 (70.6%) positive challenge patients, and 25/43 (58.1%) positive skin testing patients; these 341 patients comprised the study cohort (Table 1), giving 2,955.7 person years of prescribing data that included a total of 6,171 antibiotic dispensings.

To assess the effect of penicillin allergy assessment, antibiotic dispensing records before and after assessment were compared. In patients who were de-labeled, 215/304 (70.7%) were subsequently dispensed a penicillin antibiotic (Figure 1C), compared with 87/304 (28.6%) in the pre-assessment period; some of these pre-assessment penicillin antibiotic courses are: the change in penicillin antibiotic courses, the change in average direct cost of antibiotic, and the change in the proportion of antibiotics that were classified as broad-spectrum.

Table 1 | Characteristics of the study groups and their available dispensing data.

|                        | Penicillin allergy de-labeled | Confirmed penicillin allergic |
|------------------------|------------------------------|------------------------------|
| Age in years (SD)      | 47.49 (17.94)                | 43.50 (14.13)                |
| Female (%)             | 215 (70.72%)                 | 11 (91.67%)                  |
| Antibiotic used in     | Augmentin 280 (92%)          | Augmentin 11 (92%)           |
| challenge (%)          | Flucloxacillin 9 (2.96%)     | N/A                          |
|                        | Amoxicillin 8 (2.63%)        |                              |
|                        | Phenoxyethylpenicillin 7 (2.30%) |                  |
| Person-years of data available pre-assessment | 1,255.30 | 32.66 |
| Mean duration of dispensing data available pre-assessment (SD) | 4.13 years (2.01) | 2.72 years (1.04) |
| Total antibiotic courses pre-assessment | 2,888 | 56 |
| Person-years of data available post-assessment | 1,381.99 | 68.53 |
| Mean duration of dispensing data available post-assessment (SD) | 4.55 years (1.78) | 5.71 years (1.30) |
| Total antibiotic courses post-assessment | 2,476 | 108 |

Data are shown in three groups: penicillin allergy de-labeled (those who had a negative penicillin challenge) and confirmed penicillin allergic (divided into those with either a positive penicillin challenge or positive penicillin skin testing). There were no significant between group differences in age, duration of dispensing data available pre-assessment, or duration of dispensing data available post-assessment, by one-way ANOVA (with Sidak’s multiple comparisons test).
from 0.27 (95% CI 0.11–0.43) penicillin courses per year preassessment to 0.048 (95% CI 0.00–0.10) post-assessment. There was a reduction in mean total antibiotic courses per year from 2.298 (95% CI 2.06–2.54) to 1.79 (95% CI 1.59–1.99) in de-labeled patients (n = 304) and no change in confirmed penicillin allergic patients (n = 37), with 2.75 (95% CI 1.59–3.91) and 2.33 (95% CI 1.33–3.33) courses dispensed per year before and after assessment, respectively (Supplementary Figure 1).

For clinical reasons, the total number of annual antibiotic courses is likely to differ between patients. To control for this, dispensing of penicillin antibiotics as a proportion of total antibiotic courses was calculated for each de-labeled patient before and after penicillin allergy de-labeling (n = 304, Figure 1B). The mean percentage of a patient’s total dispensed antibiotic courses that were penicillin antibiotics increased from 12.81% (95% CI 9.88–15.73) prior to de-labeling to 39.62% (95% CI 35.68–43.57) following de-labeling. In those with confirmed penicillin allergy, the mean percentage of antibiotic courses per patient that were penicillin antibiotics decreased from 17.87% (95% CI 7.34–28.39) to 2.02% (95% CI –0.29–4.32).

The effect of penicillin allergy de-labeling on the use of nonpenicillin antibiotics was assessed by comparing non-penicillin...
antibiotic dispensing rates before and after de-labeling (n = 304, Figure 2A). Macrolide use reduced from 0.63 (95% CI 0.54–0.72) courses per year pre-assessment to 0.28 (95% CI 0.21–0.35) post-assessment. Taken together, trimethoprim and co-trimoxazole use reduced from 0.32 (95% CI 0.22–0.42) courses per year pre-assessment to 0.14 (95% CI 0.11–0.18) post-assessment. Cephalexin use reduced from 0.30 (95% CI 0.23–0.37) courses per year pre-assessment to 0.15 (95% CI 0.10–0.21) post-assessment. Fluoroquinolone use reduced from 0.29 (95% CI 0.22–0.36) courses per year pre-assessment to 0.09 (95% CI 0.06–0.13) post-assessment. Tetracycline use reduced from 0.26 (95% CI 0.21–0.32) courses per year pre-assessment to 0.17 (95% CI 0.14–0.21) post-assessment. Other non-penicillin antibiotic use reduced from 0.25 (95% CI 0.19–0.31) courses per year pre-assessment to 0.14 (95% CI 0.09–0.19) post-assessment.

Non-penicillin antibiotic use was also measured as a proportion of each de-labeled patient’s total antibiotic use before and after penicillin allergy de-labeling (n = 304, Figure 2B). Macrolide use reduced from 27.25% (95% CI 23.94–30.57) to 14.15% (95% CI 11.49–16.81) of dispensed antibiotic courses. Taken together, trimethoprim and co-trimoxazole use reduced from 12.34% (95% CI 9.86–14.81) to 8.14% (95% CI 6.10–10.18) of dispensed antibiotic courses. There was no change in tetracycline use; 12.12% (95% CI 9.70–14.54) vs. 9.56% (95% CI 7.46–11.67) of dispensed antibiotic courses. Cephalexin use reduced from 10.77% (95% CI 8.65–12.9) to 6.99% (95% CI 5.13–8.84) of dispensed antibiotic courses. Fluoroquinolone use reduced from 8.99% (95% CI 7.04–10.93) to 3.99% (95% CI 2.61–5.36) of dispensed antibiotic courses. Other non-penicillin antibiotic use reduced from 8.49% (95% CI 6.84–10.14) to 5.71% (95% CI 4.23–7.19) of dispensed antibiotic courses. The spectrum of antibiotics dispensed was categorized as described previously (Supplementary Table 1) (23). On average, prior to de-labeling, 39.76% (95% CI 36.14–43.37) of antibiotic courses dispensed to a given patient were broad-spectrum whereas, after de-labeling, 30.53% (95% CI 27.42–33.64) were broad-spectrum (p < 0.001, Figure 1D). In a crude analysis, the direct antibiotic cost was $5.78 per course prior to de-labeling and $4.13 per course following de-labeling. The cost of antibiotics was $13.30 per patient-year prior to penicillin allergy de-labeling and $7.38 per patient-year following penicillin allergy de-labeling.

DISCUSSION

Penicillin allergy de-labeling is increasingly recognized as safe and has the potential to impact antibiotic prescribing. However,
long-term, high-quality data on antibiotic use following penicillin allergy de-labeling is limited. In this pre- and post-study, penicillin antibiotic use increased significantly in those who had their penicillin allergy removed following an observed challenge. After de-labeling, 70.6% of patients went on to use a penicillin antibiotic over a mean follow up period of 4.55 years. Further, patients who had their penicillin allergy confirmed had a lower penicillin antibiotic dispensing rate post-assessment, indicating that there may be benefits of undergoing assessment with skin testing and/or an observed penicillin challenge even for patients who are confirmed to be allergic to penicillin.

Our findings support those from patients enrolled in a study of penicillin skin testing reagents, 94/196 (47%) received at least one penicillin antibiotic in the year following negative skin testing compared with 40/196 (20%) in the year prior (24). At a median follow-up of 15 months following de-labeling by skin testing and oral challenge, 64/163 (39%) de-labeled patients reported that they had taken a beta lactam antibiotic (17). A recent study with longer follow-up (mean 56 months) reported that penicillin antibiotics were taken by 447/639 (70%) de-labeled patients, measured partly by antibiotic purchasing records and partly by self-reported antibiotic use (18).

In de-labeled patients, the increased use of penicillin antibiotics in our study did not result in an overall increase in antibiotic use; total antibiotic use was lower following de-labeling. At 0.80 (95% CI 0.67–0.93) penicillin courses per patient per year, penicillin use in our de-labeled cohort exceeded the national rate of 0.48 penicillin antibiotic courses per year (25), likely reflecting selective referral of patients with high antibiotic requirements to a specialist clinic and the inclusion criteria necessitating an antibiotic dispensing record in the pre- or post-assessment period. As a key limitation, no data on inpatient antibiotic use was available. In our cohort, which is likely to be skewed toward those with a high antibiotic need and frequent contact with the health system, inpatient antibiotic consumption may be higher than the 5% average rate in New Zealand. Penicillin antibiotics are often cheaper than alternatives. In a crude analysis limited to the direct cost rate in New Zealand. Penicillin antibiotics are often cheaper than alternatives. In a crude analysis limited to the direct cost.

In conclusion, this pre- and post-study of the effect of penicillin allergy assessment on antibiotic dispensing patterns cannot solely be attributed to the effect of the penicillin allergy assessment. Results should be interpreted acknowledging that antibiotic dispensing data were used as a surrogate for antibiotic consumption and were available for 341/543 (63%) patients assessed in the Penicillin Allergy Clinic. As a regional service, some patients attending our clinic may reside in areas outside of the greater Auckland region that is covered by the TestSafe dispensing repository. Further, patients can opt to have their dispensing data excluded from the repository and it is possible that some patients did not use any antibiotics in the pre- and post-assessment periods (although referrals to this clinic are usually prompted by a frequent requirement for antibiotics in patients with a penicillin allergy label). Clinical information on the nature of the reaction that gave rise to the penicillin allergy label was not available. We do not know whether subsequent antibiotic courses resulted in allergic or adverse drug reactions. Previous work indicates that in patients with negative skin testing, after a mean follow-up period was 4.5 years, and after exposure to a mean of 8.2 therapeutic antibiotic courses, the rate of new antibiotic “allergy” to penicillin antibiotics was 2.9% (29). Lastly, there was a marked imbalance between the small number of patients determined to be allergic, with a positive challenge or positive skin testing, and the large number of patients who were de-labeled, meaning conclusions regarding antibiotic use in the group with a confirmed penicillin allergy should be interpreted with caution.

In conclusion, this pre- and post-study of the effect of penicillin allergy assessment on antibiotic dispensing patterns demonstrates that penicillin allergy de-labeling is associated with increased penicillin antibiotic use, decreased non-penicillin antibiotic use, and reduced antibiotic costs. This study provides support for penicillin allergy evaluation in a specialist clinic as an important intervention in the era of antimicrobial stewardship. It is not clear if other de-labeling interventions delivered outside a specialist clinic, such as pharmacist-led penicillin allergy de-labeling, which have the potential to improve access to penicillin allergy de-labeling, will be associated with similar changes in antibiotic use although early data are promising (20). Whether the changes in antibiotic use associated with penicillin allergy de-labeling will abrogate other negative clinical outcomes associated with a penicillin allergy label, such as increased rates of infection with multi-resistant organisms, increased length of hospital stay, and increased health care costs, requires further investigation.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Auckland Health Research Ethics Committee (AHREC 000130). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

TH designed the study, performed data analysis, and wrote the manuscript. NA performed the dispensing data extract and data analysis. ED performed data analysis and wrote the manuscript. JC performed data entry and analysis. AF designed the study. PF designed the study and wrote the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We thank Rong Hu from the Auckland City Hospital Research Office for advice regarding statistical analyses.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/falgy.2020.586301/full#supplementary-material

REFERENCES

1. Stone Jr, CA, Trubiano J, Coleman DT, Rukasin CR, Phillips EJ. The challenge of de-labeling penicillin allergy. Allergy. 75:273–88. doi: 10.1111/all.13848
2. Trubiano JA, Mangalore RP, Baey YW, Le D, Graudins LV, Charles PGP, et al. Old but not forgotten: antibiotic allergies in general medicine (the AGM study). Med J Aust. (2016) 204:273. doi: 10.5694/mja15.01329
3. Sogn DJ, Evans R, Shepherd GM, Le D, Graudins LV, Charles PG, et al. Results of the National Institute of Allergy and Infectious Diseases collaborative clinical trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med. (1992) 152:1025–32. doi: 10.1001/archinte.1992.00040170105020
4. Caubet JC, Kaiser L, Lemaitre B, Fellay B, Gervaix A, Eigenmann PA. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol. (2011) 127:218–22. doi: 10.1016/j.jaci.2010.08.025
5. Macy E, Contrares R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol. (2014) 133:790–6. doi: 10.1016/j.jaci.2013.09.021
6. West RM, Smith CJ, Pavitt SH, Butler CC, Howard P, Bates C, et al. ‘Warning: allergic to penicillin’: association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic prescribing and health outcomes. J Antimicrob Chemother. (2019) 74:2075–82. doi: 10.1093/jac/dkt127
7. Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. (2018) 361:k2400. doi: 10.1136/bmj.k2400
8. Trubiano JA, Chen C, Cheng AC, Grayson ML, Slavin MA, Thursky KA. Antimicrobial allergy “labels” drive inappropriate antimicrobial prescribing: lessons for stewardship. J Antimicrob Chemother. (2016) 71:1715–22. doi: 10.1093/jac/dkw008
9. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site infection risk. Clin Infect Dis. (2018) 66:329–36. doi: 10.1093/cid/cix794
10. Mattingly TJ, Fulton A, Lumish RA, Williams AMC, Yoon S, Yuen M, et al. The cost of self-reported penicillin allergy: a systematic review. J Allergy Clin Immunol Pract. (2018) 6:1649–54.e4. doi: 10.1016/j.jaip.2017.12.033
11. Trubiano J, Phillips E. Antimicrobial stewardship’s new weapon? a review of antibiotic allergy and pathways to “de-labeling. Curr Opin Infect Dis. (2013) 26:526–37. doi: 10.1097/QCO.0000000000000006
12. Trubiano JA, Thursky KA, Stewardson AJ, Urbancik K, Worth LJ, Jackson C, et al. Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation. Clin Infect Dis. (2017) 65:166–74. doi: 10.1093/cid/cix244
13. Sacco KA, Bates A, Brigham TJ, Imam JS, Burton MC. Clinical outcomes following inpatient penicillin allergy testing: a systematic review and meta-analysis. Allergy. (2017) 72:1288–96. doi: 10.1111/all.13168
14. Gadde J, Spence M, Wheeler B, Adkinson NF. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA. (1993) 270:2456–63.
15. Borch JE, Andersen KE, Bindslev-Jensen C. The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population. Basic Clin Pharmacol Toxicol. (2006) 98:357–62. doi: 10.1111/j.1742-7843.2006.pto.230.x
16. Tan N, Holmes NE, Chua KY, Stewardson AJ, Trubiano JA. Long-term impacts of antibiotic allergy testing on patient perceptions and antibiotic utilization. JAC-Antimicrobial Resist. (2019) 1:dlz058. doi: 10.1093/jac/dlz058
17. Bourke J, Pavlos R, James I, Phillips E. Improving the effectiveness of penicillin allergy de-labeling. J Allergy Clin Immunol Pract. (2015) 3:365–74.e1. doi: 10.1016/j.jaip.2014.11.002
18. Lachover-Roth I, Sharon S, Rosman Y, Meir-Shafrik K, Confino-Cohen R. Long-term follow-up after penicillin allergy delabeling in ambulatory patients. J Allergy Clin Immunol Pract. (2019) 7:31–5.e21. doi: 10.1016/j.jaip.2018.04.042
19. Gerace KS, Phillips E. Penicillin allergy label persists despite negative testing. J Allergy Clin Immunol Pract. (2015) 3:815–6. doi: 10.1016/j.jaip.2015.05.019
20. Du Plessis T, Walls G, Jordan A, Holland DJ. Implementation of a pharmacist-led penicillin allergy de-labeling service in a public hospital. J Antimicrob Chemother. (2019) 74:1438–46. doi: 10.1093/jac/dky575
21. Ryan K, Norris P, Becket G. Capturing data on medicines usage: the potential of community pharmacy databases. N Z Med J. (2005) 118:U1677. Available online at: http://www.nzma.org.nz/journal/118-1223/1677/
22. Duffy E, Ritchie S, Metcalfe S, Van Bakel B, Thomas MG. Antibacterials dispensed in the community comprise 85%–95% of total human antibacterial consumption. J Clin Pharm Ther. (2018) 43:59–64. doi: 10.1111/jcpt.12610
23. ECDC, EFSA Panel on Biological Hazards (BIOHAZ), EMA Committee for Medicinal Products for Veterinary Use (CVMP). ECDC, EFSA and EMA Joint Scientific Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals. EFSA J. (2017) 15:5017–70. doi: 10.2903/j.efsa.2017.5017
24. Macy E. Elective penicillin skin testing and amoxicillin challenge: effect on outpatient antibiotic use, cost, and clinical outcomes. J Allergy Clin Immunol. (1998) 102:281–5. doi: 10.1016/j.jaci.1997.08.025
25. New Zealand Ministry of Health. Pharmaceutical Data Web Tool. Pharmaceutical Data Web Tool Version 26 September 2019. https://minhealthnz.shinyapps.io/pharmaceutical_data_web_tool/ (accessed March 26, 2019).

Hills et al. Allergy De-labeling and Antibiotic Use December 2020 | Volume 1 | Article 586301
26. Macy E, Shu YH. The effect of penicillin allergy testing on future health care utilization: a matched cohort study. J Allergy Clin Immunol Pract. (2017) 5:705–10. doi: 10.1016/j.jaip.2017.02.012

27. Vyles D, Chiu A, Routes J, Castells M, Phillips EJ, Kibicho J, et al. Antibiotic use after removal of penicillin allergy label. Pediatrics. (2018) 141:e20173466. doi: 10.1542/peds.2017-3466

28. bpacnz. Antibiotics: Choices for Common Infections. Available online at: https://bpac.org.nz/antibiotics/guide (accessed July 21, 2018).

29. Macy E. Adverse reactions associated with therapeutic antibiotic use after penicillin skin testing. Perm J. (2011) 15:31–7. doi: 10.7812/tpp/11-025

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hills, Arroll, Duffy, Capstick, Jordan and Fitzharris. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.